Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study

Skin Cancer

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Int J Cancer

Gutzmer R, Weichenthal M, Eigentler T, Mohr P, Sickmann T, Dücker P, Gebhardt C, Haferkamp S, Kähler KC, Meier F, Pföhler C, Sindrilaru A, Terheyden P, von Wasielewski I, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D

doi: 10.1002/ijc.70440

Genitourinary Cancer

Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study

Lancet Oncol

Soeterik TFW, Miszczyk M, Peters M, Bilski M, Francolini G, Garlatti P, Nicosia L, Alongi F, Mezeckis M, Kociolek J, Greco C, Techmański T, Huele EH, Teunissen FR, Westhoff PG, Vis W, Haverkort MAD, van der Voort van Zyp JRN, Intven MPW, van der Velden JM, Shariat SF, Eppinga WSC

doi: 10.1016/S1470-2045(25)00717-X

Lung, Respiratory and Thoracic Cancer

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

Lung Cancer

Frehner L, Schär S, Hayoz S, Petermichl V, Speicher P, I Rothschild S, Mauti LA, König D, Finazzi T, Froesch P, Marini S, Allemann A, Mark M, Janthur WD, Stamatiou A, Metaxas Y, Ermiş E, Wagner F, Früh M, Schmid S

doi: 10.1016/j.lungcan.2025.108813

Lung, Respiratory and Thoracic Cancer

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Lung Cancer

Huijs JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, Bensch F, Hijmering-Kappelle LBM, de Schrevel TMT, van Geffen WH, Youssef-El Soud M, Steens MMH, Pitz C, De Ruysscher DKM, Hendriks LEL

doi: 10.1016/j.lungcan.2025.108745

Lung, Respiratory and Thoracic Cancer

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Transl Lung Cancer Res

Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L

doi: 10.21037/tlcr-24-881

Skin Cancer

A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy

Clin Cancer Res

Bhanja D, Zhu J, Wilding H, Benavides-Vasquez J, de Macedo Filho L, Ozair A, Moeckel C, Badani A, Hong J, Sivik J, Drabick JJ, Pameijer CR, Margolin K, Ahluwalia M, Mansouri A

doi: 10.1158/1078-0432.CCR-24-2681

Skin Cancer

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study

Eur J Cancer

Albrecht LJ, Garnier J, Zaremba A, Brauch L, Brunnert F, Rauschenberg R, Forschner A, Vazquez XG, Mangana J, Erdmann M, Angela Y, Franklin C, Tietze J, Lodde G, Tasdogan A, Seier JA, Roesch A, Ugurel S, Berking C, Gutzmer R, Heinzerling L, Meier F, Mohr P, Hassel JC, Schadendorf D, Livingstone E, Zimmer L

doi: 10.1016/j.ejca.2026.116595

Genitourinary Cancer

Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

Int J Cancer

Molina-Cerrillo J, Roviello G, Bourlon MT, Studentova H, Fiala O, Cerbone L, Kucharz J, Ansari J, Zeppellini A, Taha T, Buti S, Ürün Y, Scagliarini S, Li H, Sunela K, Park SH, Rizzo M, Zgura A, Chiari R, Seront E, Catalano M, Ghosn M, Filosa A, Soares A, Massari F, Monteiro FSM, Grande E, Porta C, Bracarda S, Santoni M

doi: 10.1002/ijc.70228

Skin Cancer

Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment

J Clin Oncol

Sperduto PW, Marqueen KE, Chang E, Li J, Davies MA, Ebner DK, Breen WG, Lamba N, Shih HA, Edwards D, Kim MM, Mahal A, Rahman R, Ankrah N, Boggs DH, Lewis C, Hyer D, Buatti JM, Johri F, Soliman H, Masucci L, Roberge D, Aneja S, Chiang V, Phuong C, Braunstein S, Dajani S, Sachdev S, Wan Z, Niedzwiecki D, Vaios E, Kirkpatrick JP, Pasetsky J, Wang TJC, Kutuk T, Kotecha R, Ross RB, Rusthoven CG, Nakano T, Tawbi HA, Mehta MP

doi: 10.1200/JCO-24-01351

Related content

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study

First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study

Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment